Cerebral blood flow and its pathophysiology in hypertension

Research output: Contribution to journalJournal articleResearchpeer-review

In chronic hypertension, the lower limit of autoregulation of cerebral blood flow (CBF) is shifted towards high blood pressure with a consequent impairment of the tolerance to acute hypotension. Despite this, antihypertensive treatment in the great majority of patients prevents stroke and the risk for treatment-induced cerebral ischemia is only real in a limited number of clinical settings such as malignant hypertension, hypertension in the elderly, and hypertension associated with acute stroke. During long-term treatment adaptive hypertensive changes in CBF autoregulation may be reversible, especially in young patients. Drugs used for emergency lowering of blood pressure may be classified into four groups according to their effect on CBF and intracranial pressure: (1) drugs with no pharmacological action in the cerebral circulation; (2) cerebral vasodilators; (3) alpha-adrenergic and ganglionic blockers; and (4) angiotensin-converting enzyme (ACE) inhibitors. Oxygen saturation in the jugular venous blood is of the order of 60% to 70% and is considerably higher than in the coronary sinus. It is hypothesized that this oxygen reserve enables the brain better than the heart to take hemodynamic advantage of pressure lowering without risking tissue ischemia. This may explain why antihypertensive treatment prevents stroke but not myocardial infarction. Acute hypertensive encephalopathy is probably caused by failure of autoregulatory vasoconstriction with focal or generalized dilatation of small arteries and arterioles. This is associated with a high CBF, dysfunction of the blood-brain barrier, and the formation of brain edema that is thought to cause the clinical symptoms.

Original languageEnglish
JournalAmerican Journal of Hypertension
Volume2
Issue number6 Pt 1
Pages (from-to)486-92
Number of pages7
ISSN0895-7061
DOIs
Publication statusPublished - Jun 1989

    Research areas

  • Animals, Antihypertensive Agents/adverse effects, Brain Diseases/etiology, Brain Ischemia/chemically induced, Cerebrovascular Circulation/drug effects, Cerebrovascular Disorders/prevention & control, Emergency Medical Services, Homeostasis/drug effects, Humans, Hypertension/complications, Myocardial Infarction/etiology, Risk Factors

ID: 275592193